Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Profile and Safety of Fp/ABS eMDPI Compared to Fp MDPI in Children With Asthma
NCT06290102Phase 1Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate nasal spray and salbutamol in asthma (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Maximum Observed Plasma Drug Concentration of Fluticasone Propionate, Maximum Observed Plasma Drug Concentration of Albuterol Sulfate and 12 more. Started May 2024; status: completed.
02
Drugs
fluticasone propionate nasal spraysalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06290102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290102.